Reed MB, Domenech P, Manca C et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004; 431: 84 – 7.
2.
Antoine D, Maguire H, Story A. Epidemiology and response to the growing problem of tuberculosis in London. Euro Surveill 2006; 11: 25 – 8.
3.
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158 – 63.
4.
Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis – persistence, patience, and winning by waiting. Nature Med 2000; 12: 1327 – 9.
5.
Chan J, Flynn J. The immunological aspects of latency in tuberculosis. Clin Immunol 2004; 110: 2 – 12.
6.
Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of the primary infection or exogenous reinfection? Am Rev Resp Dis 1967; 95: 729 – 45.
7.
van Rie A, Warren R, Richardson M et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174 – 9.
8.
Fine PE, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med 1999; 341: 1226 – 7.
9.
Lillebaek T, Dirksen A, Baess I et al. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Inf Dis 2002; 185: 401 – 4.
10.
Lillebaek T, Dirksen A, Vynnycky E et al. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis 2003; 188: 1032 – 9.
11.
Hernandez-Pando R, Jeyanathan M, Mengistu G et al. Persistence of DNA from M. tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000; 356: 2133 – 8.
12.
Farah MG. Tuberculosis in Norway with emphasis on immigrants. Doktoravhandling. Oslo: Det medisinske fakultet, Universitetet i Oslo, 2006.
13.
Farah MG, Tverdal A, Selmer R et al. Tuberculosis in Norway by country of birth, 1986 – 1999. Int J Tuberc Lung Dis 2003; 7: 232 – 5.
14.
Farah MG, Meyer HE, Selmer R et al. Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol 2005; 34: 1005 – 11.
Farah MG, Tverdal A, Steen TW et al. Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005; 5: 14.
17.
Klouman E, Winje BA, Heldal E. Rutiner for å sikre at asylsøkere med tuberkulose kan bli i Norge under behandling. MSIS-rapport 2005; 33: 29.
18.
Farah MG, Rygh JH, Steen TW et al. Patient and health care system delays in the start of tuberculosis treatment in Norway. BMC Infect Dis 2006; 6: 33.
19.
Jenum AK, Holme I, Graff-Iversen S, Birkeland KI. Ethnicity and sex are strong determinants of diabetes in an urban Western society: implications for prevention. Diabetologica 2005; 48: 435 – 9.
Kommentarer
( 0 )
Dette kommentarfeltet modereres, men kommentarer blir ikke redaksjonelt behandlet ut over å sikre at de følger retningslinjer for vårt kommentarfelt.
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
Publisert: 19. oktober 2006
Utgave 20, 19. oktober 2006
Tidsskr Nor Lægeforen 19. oktober 2006
Manuskriptet ble mottatt 21.6. 2006 og godkjent 29.6. 2006. Medisinsk redaktør Jan C. Frich.
Får du ikke vist PDF-filen eller vil lagre filen, kan du høyreklikke på PDF-ikonet. Velg «Lagre mål/fil som..» og hent så opp PDF-filen i for eksempel Acrobat Reader.